Skip to content
AnalystLens

TransUnion Annual Report, Year Ended Dec 31, 2022

Filing Date
Filed February 14, 2023
Period End
December 31, 2022
Security
TRU
In the record · 2016–202610-K1110-Q348-K131

TRU filed 11 annual reports (10-K), 34 quarterly reports (10-Q) and 131 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jun ’18Jun ’18
  2. Auditor change8-K · Feb ’20Feb ’20
  3. Leadership change8-K · Mar ’22Mar ’22
  4. Leadership change8-K · Nov ’26Nov ’26

Summary

Summary of the 10-K filed February 14, 2023. Cited figures are marked; the original filing is the authoritative source.

TransUnion's 10-K for fiscal 2022 reports revenue of $3,709.9 milliona, up 25.3% from $2,960.2 million in 2021, driven mainly by the Neustar and Argus acquisitions and partly offset by macroeconomic weakness and a 2.3% foreign currency headwind.

Net income attributable to TransUnion fell to $269.5 millionb from $1,387.1 million, but the prior year included a $982.5 million gain on the sale of the Healthcare business. Consolidated Adjusted EBITDA rose to $1,346.5 million from $1,156.9 million, while the Consolidated Adjusted EBITDA margin declined to 36.3% from 39.1%, which management attributes primarily to lower margins from recent acquisitions. Adjusted diluted earnings per share were $3.62, compared with $3.44.

Balance sheet leverage increased. Total debt was $5,670.1 millionc and cash was $585.3 million at December 31, 2022, yielding a Leverage Ratio of 3.8, up from 3.5 a year earlier. Cash provided by operating activities fell to $297.2 million from $808.3 million, reflecting payment of taxes on the Healthcare divestiture gain and higher interest expense of $230.9 million.

The company completed the $505.7 milliond acquisition of Verisk Financial Services (Argus) in April 2022, sold its non-core VF businesses in December 2022 for total proceeds of $173.9 million, and prepaid $600.0 million of Senior Secured Term Loans during 2022. Key risks disclosed include a pending Consumer Financial Protection Bureau lawsuit against TransUnion entities, for which an accrued liability of $56.0 million is recorded and a loss in excess of the accrual is reasonably possible.

The company also disclosed a CFPB and FTC matter related to its tenant screening business, a CFPB security freeze investigation, and a Department of Justice inquiry relating to Argus, with Verisk agreeing to indemnify certain losses. Goodwill of $5,551.4 million passed the 2022 impairment test, although the United Kingdom reporting unit's excess fair value over carrying value was less than 10%.

Key Highlights

  1. Revenue rose 25.3% to $3,709.9 million in 2022, with a 24.4% contribution from recent acquisitions and a 2.3% decrease from foreign currency.
  2. Net income attributable to TransUnion was $269.5 million, down from $1,387.1 million, which included a $982.5 million gain on the Healthcare business sale in 2021.
  3. Consolidated Adjusted EBITDA increased to $1,346.5 million, but the margin declined to 36.3% from 39.1%, mainly due to lower margins from recent acquisitions.
  4. Total debt was $5,670.1 million against cash of $585.3 million, and the Leverage Ratio increased to 3.8 from 3.5.
  5. Cash provided by operating activities fell to $297.2 million from $808.3 million, largely reflecting taxes paid on the Healthcare divestiture gain.
  6. The CFPB lawsuit carries an accrued liability of $56.0 million, with a reasonable possibility of a loss above the accrual that could have a material adverse effect.
  7. Quarterly dividends increased to $0.105 per share in the third and fourth quarters of 2022, with total dividends paid of $77.8 million.

Financial Statements

FY2022 against FY2021

Line itemFY2022FY2021Change
Revenue$3.71B$2.96B+25.3%
SG&A Expenses$1.18B$909.00M+29.7%
Operating Expenses$3.08B$2.31B+33.6%
Operating Income$626.30M$651.90M−3.9%
Interest Expense$230.90M$112.60M+105.1%
Net Income$266.30M$1.39B−80.8%
EPS (Basic)$1.38$7.26−81.0%
EPS (Diluted)$1.38$7.20−80.8%
Shares Outstanding (Basic)192.50M191.40M+0.6%
Shares Outstanding (Diluted)193.10M193.00M+0.1%

Frequently Asked Questions

  1. What drove the revenue growth in 2022?

    Revenue increased $749.7 million, or 25.3%, due primarily to a 24.4% increase from recent acquisitions in the U.S. Markets and Consumer Interactive segments and organic growth from new business wins and product initiatives. These gains were partially offset by macroeconomic weakness in several markets and a 2.3% decrease from foreign currency impacts.

  2. Why did net income drop so sharply compared with 2021?

    Net income attributable to TransUnion was $269.5 million in 2022 versus $1,387.1 million in 2021. The 2021 result included discontinued operations of $1,031.7 million, mainly from the $982.5 million gain on the sale of the Healthcare business. Income from continuing operations attributable to TransUnion was $252.1 million in 2022 compared with $355.5 million in 2021.

  3. What is the company's current debt and leverage position?

    At December 31, 2022, total debt was $5,670.1 million and cash and cash equivalents were $585.3 million, giving net debt of $5,084.8 million. The Leverage Ratio was 3.8, up from 3.5 in 2021, due primarily to lower cash after the Verisk Financial Services acquisition and the payment of taxes on the Healthcare gain. The filing states that approximately 70% of variable-rate debt is hedged with interest rate swaps.

  4. What are the most significant legal and regulatory risks?

    The CFPB filed a lawsuit in April 2022 against TransUnion entities and a former executive alleging violations of a 2017 Consent Order and deceptive marketing of credit monitoring products. The company has accrued $56.0 million for this matter and says a loss above that amount is reasonably possible. Separately, the CFPB and FTC are in settlement discussions about tenant screening practices, and a Department of Justice investigation relates to Argus's use of government contract data, which Verisk has agreed to indemnify in part.